Active Ingredient History
Golimumab is a human monoclonal antibody which is used as an immunosuppressive medication and sold under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule and hence is a TNF inhibitor. Profound reduction in C-reactive protein (CRP) levels, interleukin (IL)-6, intercellaular adhesion molecules (ICAM)-1, matrix metalloproteinase (MMP)-3, and vascular endothelial growth factor (VEGF) demonstrates golimumab as an effective modulator of inflammatory markers and bone metabolism. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Arthritis (Phase 3)
Arthritis, Juvenile (Phase 3)
Asthma (Phase 2)
Autoimmune Diseases (Phase 3)
Axial Spondyloarthritis (Phase 4)
Behcet Syndrome (Phase 2)
Colitis (Phase 4)
Crohn Disease (Phase 4)
Diabetes Mellitus, Type 1 (Phase 2)
Healthy Volunteers (Phase 1)
Inflammatory Bowel Diseases (Phase 4)
Methotrexate (Phase 4)
Sarcoidosis (Phase 2)
Spondylarthropathies (Phase 4)
Substance Withdrawal Syndrome (Phase 3)
Uveitis (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
